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Background: Follow-up studies of psoriasis patients indicate an increased risk in the occurrence of malignancies at
different sites of origin. Population stratification and/or complicated interpretation of evidence on the risk of cancer
(due to the small number of patients included in most series) lead to inconsistent data. Herein we investigated the
risk of occurrence of malignancies at different sites of origin in a series of 517 psoriasis patients and their 1st degree
relatives.
Methods: We evaluated the tumour spectrum as well as the age of the patient at diagnosis of cancers in psoriasis
families along with the observed and expected frequencies of malignancies. The distribution of 17 common
mutations/polymorphisms in 10 known cancer susceptibility genes among psoriasis patients and 517 matched
healthy controls were examined. No such study has been published to date.
Results: The statistical comparison of the observed and expected frequencies of cancers revealed a higher than
expected occurrence of Hodgkin’s lymphoma among males in psoriasis families when compared to the general
population (OR=1.8, 95%CI 1.6-2.1, p=0.002). There was a non-significant tendency towards a younger age of onset
and overrepresentation of laryngeal cancer and leukaemia in psoriasis families. We found no major differences in
the distribution of cancer susceptibility mutations among our cases and the healthy controls.
Conclusions: The results of our study suggest an increased risk of Hodgkin’s lymphoma for male members of
psoriasis families. Further studies are needed to confirm the findings and to evaluate whether or not the application
of cancer surveillance protocols for Hodgkin’s lymphoma, leukaemia and laryngeal cancer are justified in these
families.
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Psoriasis is one of the most common skin disorders, and it
is estimated that it affects 2-3% of the general Caucasian
population [1]. Psoriasis is a chronic inflammatory skin
disorder characterised by keratinocyte hyperproliferation
and increased cutaneous blood flow induced via stimula-
tion of tissue resident immune cells and a marked alter-
ation of cytokine profiles [2]. Current evidence suggests
that psoriasis is an immune-mediated disorder, and in-
novative therapies involved in the suppression of immune
responses, such as T-cell-targeted agents and tumour* Correspondence: debniak@pum.edu.pl
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reproduction in any medium, provided the ornecrosis factor (TNF) inhibitors, have improved the out-
come of the disease [3,4]. As judged by twin- and large
population-based genetic studies, the disease seems to
have a strong genetic component – disease concordance
in monozygotic twins is at most 70%, and the sibling re-
currence risk of PsV has been estimated to range between
4 and 11 [5]. As of the publication of this writing, the mo-
lecular background of this disease remains unclear [6].
At present it is generally accepted that the disease is both
multifactorial and genetically heterogeneous. GWAS stud-
ies identified several loci that are associated with psoriasis
[7,8]. Recently 15 new susceptibility loci (which included
candidate genes whose products are involved in innate host
defense) have been revealed, increasing to 36 the number
associated with psoriasis in European individuals [9].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creased risk in the occurrence of malignancies at differ-
ent sites of origin. Some reports suggest more common
development of non-melanoma skin cancer among psor-
iasis patients [10-13]. Results of other studies point to
the increased frequency of other neoplasms, such as
cancers of the larynx, lung, colon, kidney, pancreas and
non-Hodgkin's lymphoma [12,14-16]. Unfortunately,
data from literature is not entirely consistent. According
to Alderson and Clark, cancers of the skin, stomach or
lung are not associated with psoriasis [17]. In a recent
study of Finnish psoriasis patients, the estimated relative
risk was higher for Hodgkin’s and non-Hodgkin’s lymph-
omas, squamous skin cancer and laryngeal cancers; the
risk for other malignancies (such as colon, lung or kid-
ney) was unchanged when compared to the general
population [18].
Exposure to UVA and UVB (used in the treatment of
psoriasis) most likely increases the risk of malignant
melanoma [19,20]. According to Lee et al., melanoma
and lymphoma are overrepresented among severe psor-
iasis patients [21]; however, the risk of malignant melan-
oma was reported to be diminished among psoriasis
patients in other studies [15,18].
Inconsistent data from literature can occur due to
population stratification and/or complicated interpret-
ation of evidence on the risk of cancer due to the small
number of patients included in most series, precluding a
full evaluation of rare neoplasms. Furthermore, the se-
lection of patients in a clinical series might result in as-
sessment of the effect of special types of therapies used
in subsets of patients.
Herein we have investigated the risk of occurrence of
malignancies of a different site of origin in a series of
517 psoriasis patients and their 1st degree relatives. We
evaluated the tumour spectrum and age of diagnosis of
cancers diagnosed in PsV families, as well as the ob-
served and expected frequencies of malignancies.
Mutations/polymorphisms of many cancer susceptibil-
ity genes (such as BRCA1, CDKN2A, XPD, VDR, etc.)
lead to tumour development. Some of these “cancer risk”
gene alterations were also reported to be associated with
psoriasis risk [22-24]. To evaluate the possible link be-
tween psoriasis and cancer, we examined the distribution
of 17 mutations/polymorphisms in 10 known cancer
susceptibility genes among patients and 517 matched
healthy controls.
No such study has been published to date.
Patients and methods
Patients
The case group consisted of 517 (218 women and 299
men, mean age 42.9) unselected, consecutive patients
with psoriasis vulgaris (PsV) from North-western Poland.Patients were recruited between 2010 and 2012 from
outpatient clinics and hospital wards of the two partici-
pating dermatology departments: The Chair and Clinic
of Skin and Venereal Diseases, PMU, Szczecin; and The
Clinic of Dermatology and Venereology, PUMS, Poznań.
Participation rates were over 80% for both centres. All
patients were at least 18 years old, although the disease
could have been diagnosed at an earlier age.
A detailed history of ancestry and clinical data
concerning the age of the patient at diagnosis, the family
history of psoriasis, smoking habits, personal cancer his-
tory and family cancer history was collected.
Controls consisted of 517 healthy adults, who were
gender and age-matched case by case. All controls came
from the West Pomerania region of Poland. Control
samples were selected from a population-based study of
1.5 million individuals from West Pomerania who were
enrolled in a study aimed at identifying familial aggrega-
tions of malignancies, which was recently performed by
our centre. Individuals with psoriasis or a positive family
history of psoriasis or cancer were excluded from the
control group.
The study conformed to the Declaration of Helsinki,
and all participants signed a form of consent prior to the
donation of a blood sample. The study was approved by
the institutional review board of the Pomeranian Med-
ical University.
Methods
In the first stage of the study, we compared frequencies
of malignant tumour occurrence and the age of the pa-
tient at diagnosis in PsV families against those of the
general Polish population. We evaluated malignancies
affecting probands and their 1st degree relatives.
For statistical analyses, the Chi-Square test, U-test and
odds ratio were utilised. Additional analyses performed
in PsV families included the comparison of observed fre-
quencies (OF) with expected frequencies (EF) and the
relative risk (RR) of occurrence of malignancies at differ-
ent sites of origin. OF and EF were calculated through
evaluation of the total number of family members and
affected cases in different age groups (range of 5 years)
in PsV families in comparison to age-specific incidence
rates in different age groups (range of 5 years) per
100,000 people. These calculations were done by site
with individuals registered in the general population of
Poland [25]. Bonferroni correction was used for multiple
testing.
In the second stage of the study, we compared the
prevalence of common alterations in DNA reported in
literature to cancer susceptibility alterations among PsV
patients, healthy controls and the general Polish popula-
tion (data obtained from published reports). We geno-
typed founder BRCA1 mutations (5382insC, C61G,
Maleszka et al. Hereditary Cancer in Clinical Practice 2013, 11:6 Page 3 of 7
http://www.hccpjournal.com/content/11/1/64153delA), common variants of XPD (D312M, K751Q),
NOD2 (3020insC), CDKN2A (A148T), CHEK2 (CHIVS2,
I157T), VDR (M1T), p53 (P72R), ATM (E1978X), MC1R
(R160W, R151C, R163Q), MTHFR (A222V) and rs67
(rs6983267).
DNA samples were obtained from the peripheral blood
of individuals. All SNPs were analysed by real-time PCR,
using a LightCycler480 from Roche. The analyses were
performed using the TaqMan(R) genotyping assay, which
consists of sequence specific primers and oligonucleotide
fluorescent labelled probes, enabling amplification of the
examined fragments and further allele discrimination.
Randomly selected probes were sequenced to confirm
the results of real-time PCR.
Power calculations were done a posteriori based on
the observed versus expected frequencies, the number of
individuals analysed and the threshold p-value (after cor-
rection for multiple testing by Bonferroni). The signifi-
cance threshold for the p-value was 0.05/24 for analysis
of the genetic markers, and in the case of analysis via
the cancer site, the threshold was 0.05/19 for womenTable 1 Proportion and age at diagnosis of malignancies of d
population









Breast 0 ND^ 0,2 64,1
Lungs 24,4 59,4 21,1 65,9
Colorectal 14,1 60,6 12,4 67,2
Stomach 4,7 65,6 4,9 66,4
Prostate 14,1 66,1 13,2 70,1
Kidney 3,8 67,5 4,1 63
Larynx 7,5 56,5 2,7 62,4
Melanoma 1,9 ND 1,7 60,4
Skin 1,9 ND 6,8 69,3
Leukaemia 4,7 52,6 2,2 56,9
Cervix - - - -
Liver 4,7 59,2 1,2 65,8
CNS 5,7 54,2 2,4 55,3
Bladder 1,9 ND 7,0 68,3
Pancreas 1,9 ND 2,3 64,7
Uterus - - - -
FGT* - - - -
Hodgkin’s
Disease
1,9 ND 0,5 39,6
NHLs 0,9 ND 1,4
#- general Polish population, according to data published by National Cancer Regis
^ND-not done-mean age was calculated for malignancies affecting at least 5 individ
*-p<0.05, statistically significant, FGT-female genital tract- site of origin could not beand 0.05/17 for men (0.05 divided by the amount of hy-
potheses tested for the same group).Results
Evaluation of the tumour spectrum revealed no statisti-
cally significant differences between proportions of ma-
lignancies observed in our PsV families when compared
to the general population (Table 1). Analysis of the mean
age of diagnosis (performed in our families for cancers
affecting at least 5 cases) also revealed no significant dif-
ferences between malignancies diagnosed among mem-
bers of PsV families and the general population.
There was a tendency for an earlier appearance of leu-
kaemia (~4 years), laryngeal cancer (~6 years) and mel-
anoma (among males ~6 years) in PsV families (Table 1).
We observed 196 cancers among 3252 members of
517 psoriasis families. In comparison to the expected
frequency (190 tumours), the difference was not signifi-
cant (p=0.7931), neither for males (p=1.0) nor females














17,1 56,8 22,4 60,2
11,1 57,2 8,6 65,1
7,7 64,8 10,1 68,3
1,7 ND^ 2,7 68,6
- - - -
5,1 63,3 2,8 65,2
0,8 ND 0,4 62,2
4,3 52,6 1,9 58,7
3,4 ND 7,5 70,2
4,3 58,2 1,9 62
6 58,5 4,4 56,8
8,5 63,7 0,8 69,7
6,8 61 2,3 59,3
0 ND 2,0 68
2,6 ND 2,3 69,2
2,6 65,6 7,3 63,6
9,4 48,6* 17,8 68,8*





Table 2 Expected and observed frequencies, related risk
of occurrence of malignancies of different site of origin
in psoriasis families





(RR, CI 95%), p
Breast Females 20 21 1.0, p= 0,8736
Lungs Males 26 26 1.0, p=1.0
Females 13 9 1,2, p=0,3891
Colorectal Males 15 16 1.0, p=0,8553
Females 9 11 0.9, p=0,6518
Stomach Males 5 6 0.9, p=0,7618
Females 4 10 0.6, p=0,1066
Liver Males 1 1 1.0, p=1.0
Females 2 1 1.3,p=0,5632
Melanoma Males 2 2 1.0, p=1.0
Females 5 2 1.4, p=0,2554
Kidney Males 4 5 0.9, p=0,7378
Females 6 4 1.2, p=0,5253
Prostate Males 15 16 1.0, p=0,8553
Larynx Males 6 3 1.3, p=0,3152
Females 1 0,5 1.3, p=0,1964
CNS Males 3 2 1.2, p=0,6539
Females 4 2 1.4, p=0,4130
Leukaemia Males 5 2 1.4, p=0,2552
Females 5 2 1.4, p=0,2554
Hodgkin
Lymphoma
Males 2 0,2 1.8, p=0.002*
Females 0 0 -
Bones Males 1 1 1.0, p=1.0
Females 2 1 1.3, p=0,5632
Bladder Males 1 1 1.0, p=1.0
Females 0 2 P=0,1569
NHL Males 1 1 1.0, p=1.0
Females 1 1 1.0, p=1.0
Pancreas Males 2 3 0.8, p=0,6539
Females 3 3 1.0, p=1.0
Uterus Females 3 7 0.6, p=0,2039
Ovary Females 4 5 0.9, p=0,7379
Thyroid Males 0 0.5 P=0.0523
Females 2 2 1.0, p=1.0
Cervix Females 5 4 1.1, p=0,7379
Non-melanoma
skin cancer
Males 9 9 1.0, p=1.0
Females 9 8 1.0, p=0,8069
*p-after Bonferroni correction.
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frequencies of cancers revealed a higher than expected oc-
currence of Hodgkin’s lymphoma among males in PsV
families when compared to the general population
(OR=1.8, 95%CI 1.6-2.1, p=0.002) (Table 2). There was a
tendency, although non-significant, for melanoma overrep-
resentation among females from PsV families (OR=1.4,
p=0.26). A similar tendency for both males and females
was observed for leukaemia (OR=1.4, p=0.26) and laryn-
geal cancer (OR=1.3, p>0.19).
Molecular examination of 17 mutations/polymorphisms
in 10 cancer susceptibility genes in psoriasis patients and
controls showed no major differences in distribution of
cancer susceptibility mutations among PsV families and
healthy controls (Table 3).
For analysis of genetic markers, the statistical power a
posteriori ranges between 0.12 in the most favourable
case (marker rs6983267, variant GT) and 0.001 in the
least favourable case (marker CHK2, variant IVS2+1G>A).
Comparatively, for the most favourable case, the mini-
mum sample size for a statistical power a priori of at least
0.7 should have been great than 1800 cases and an equiva-
lent number of controls.
For analysis by cancer site, the statistical power a
posteriori ranges between 0.17 in the most favourable
case (female lung cancer) and 0.0015 in the least
favourable case (several types of cancer, e.g. male liver
cancer). Comparatively, for the most favourable case, the
minimum sample size for a statistical power a priori of
at least 0.7 should have been greater than 12400 first de-
gree relatives.
Discussion
Tumour spectrum and the age of the patient at diagnosis
of malignancies of different sites of origin observed in
our PsV families and in the general population were
similar. However, there was a higher than expected fre-
quency of the occurrence of Hodgkin’s lymphoma in
males from PsV families. We also observed a tendency
towards overrepresentation of leukaemia and laryngeal
cancer among PsV families.
Our findings are consistent with the results of a follow
up study of Swedish hospitalised psoriasis patients,
which point to a significant excess of Hodgkin’s lymph-
oma and cancers of the upper aerodigestive tract [26].
An increased risk of Hodgkin’s lymphoma and laryngeal
cancer has also been reported for Finnish hospitalised pa-
tients [18]. The association of leukaemia and psoriasis is
not well-documented. There are a series of case reports of
leukaemia developing in psoriasis patients treated with im-
munosuppressive drugs, such as cyclosporine, methotrexate
or etanercept [27-31]. Our results support the theory
that psoriasis is not associated with an increased risk of
NHL overall or of any NHL subtype [32], althoughthere are some reports suggesting that such an associ-
ation exists [16,18]. We observed a non-significant ten-
dency of melanoma overrepresentation among females
from PsV families. This insignificant correlation does
Table 3 Prevalence of the examined mutations/polymorphisms among PsV cases and healthy controls
Gene (Mutation) Cases Controls p OR
BRCA1 (ex20)(ex5-300) 2 / 507 0,39% 1) / 510 0,20% 0,5597 2,016
1 / 507 0,20% 0 0,3156 3,024
CHK2 (I157T) 22 (+) / 503 4,37% 28 (+) / 507 5,52% 0,4000 0,7824
CHK2 (IVS2+1G>A) 2 (+) / 503 0,40% 2 (+) / 507 0,39% 0,9937 1,008
NOD2 (3020insC) 43 (+) / 500 8,60% 41 (+) / 510 8,04% 0,7469 1,076
XPD 936 (D312M) CT TT 200 / 491 40,73% 199 / 493 40,37% 0,9064 1,015
127 / 491 25,87% 114 / 493 23,12% 0,3173 1,160
XPD 2253 (K751Q) GT GG 240 / 503 47,71% 240 / 510 47,06% 0,8347 1,027
82 / 503 16,30% 89 / 510 17,45% 0,6255 0,9213
MC1R (R151C) CT TT 33 / 428 7,71% 35 / 501 6,99% 0,6727 1,112
0 / 428 0% 2 / 501 0,40% 0,1907 0,2331
MC1R (V60L) GT TT 50 / 448 11,16% 63 / 510 12,35% 0,5681 0,8914
1 / 448 0,22% 6 / 510 1,18% 0,0839 0,1879
MC1R (R163Q) AG AA 30 / 435 6,90% 37 / 501 7,38% 0,7724 0,9289
1 / 435 0,23% 2 / 501 0,40% 0,6476 0,5749
VDR (M1T) AG AA 240 / 490 48,98% 252 / 508 49,61% 0,8431 0,9752
99 / 490 20,20% 99 / 508 19,49% 0,7768 1,046
CDKN2A (A148T) 26 (+) / 501 5,19% 28 (+) / 511 5,48% 0,8375 0,9442
p53 (P72R) CG CC 192 / 503 38,17% 195 / 512 38,09% 0,9778 1,004
34 / 503 6,76% 33 / 512 6,44% 0,8403 1,052
rs6983267 GT TT 261 / 501 52,10% 234 / 509 45,97% 0,0516 1,278
119 / 501 23,75% 123 / 509 24,17% 0,8779 0,9776
ATM (E198X) 0 (+) / 499 0% 0 (+) / 508 0% - -
MTHFR (A222V) CT TT 223 / 488 45,70% 227 / 499 45,49% 0,9483 1,008
47 / 488 9,63% 44 / 499 8,82% 0,6587 1,102
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ing the association of melanoma with psoriasis. We
show that the risk of melanoma is not significantly in-
creased for individuals from PsV families.
Due to the relatively small numbers of cases, both type
1 and 2 statistical errors cannot be excluded; the results
thus need to be verified by examination of a larger series
of patients. The current study lacks the statistical power
to confirm if the absence of observed association is due
to a true lack of association or rather due to an insuffi-
cient sample size. The current research should be con-
sidered only as an exploratory study attempting to reveal
interesting tendencies worthy of in-depth analysis at a
later stage.
Assessing the risk of cancer as a single outcome re-
vealed no statistically significant association between
psoriasis and cancer. It indicates that the common tu-
mours (such as cancers of the breast, prostate, lung or
colon) constituting the majority of neoplasms are not
strongly linked with psoriasis. However, it does not ex-
clude a moderate association for rare malignancies.The results of molecular genotyping of mutations/
polymorphisms present in cancer susceptibility genes re-
vealed no differences in the prevalence of the examined
alterations between cases and controls. It seems that
none of the examined alterations in DNA are associated
with psoriasis. This is the first such study evaluating any
linkage between the BRCA1 gene (predisposing to breast
and ovarian cancer), CHEK2 gene (cancers of the
prostate, thyroid, breast, colon, stomach), MC1R gene
(melanoma, non-melanoma skin cancers), ATM gene
(cancers of the breast, pancreas, thyroid) and the XPD
gene (melanoma, oesophageal squamous cell carcinoma,
cancers of the lung and breast) with psoriasis. Our re-
sults are consistent with current data in literature,
suggesting that NOD2 (colorectal and breast cancer),
p53 (cancers of the cervix, bladder, prostate, breast) and
MTHFR (oesophageal and cervical cancers) might not
be susceptibility genes for psoriasis [33-36]. Our findings
support the thesis that the VDR gene (predisposing to
melanoma and breast cancer) does not show a robust
and reproducible association with the risk of psoriasis
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[22,23,38], any association that may exist is likely to be
weak and potentially restricted to specific populations.
Down-expression of another cancer susceptibility gene,
CDKN2A (predisposing to melanoma, cancers of the
pancreas, breast and lung), led to speculation that the
gene may have a role in the pathogenesis of psoriasis
[24]. Our findings do not support this thesis.
According to many follow-up studies, there is an in-
creased risk of the most common human malignancy,
basal cell cancer (BCC), among psoriasis patients
[10-13]. In a recent study, genetic susceptibility to basal
cell carcinoma (BCC) among Danish psoriatic patients
was investigated and confirmed previous reports that
XPD may predispose to BCC [39-41]. Interestingly, we
did not observe any excess of non-melanoma skin can-
cers in our families and found no association of XPD
common variants with psoriasis. This lack of association
suggests that the risk is restricted to individuals treated
with phototherapy, which constituted only a small pro-
portion of the individuals in our PsV families.
In conclusion, the results of our study indicate a mod-
erate association between psoriasis and familial cancer
risk. These results also suggest an increased risk of
Hodgkin’s lymphoma for male members of PsV families.
Further studies are needed to confirm the findings and
to evaluate whether or not cancer surveillance protocols
are justified in these families.
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